In addition, ICPI biomarkers of TMB-High (54.4% [1680/3035] vs 33.6% [2442/7277], P = 1.30E−91), STK11 mutations (17.7% [538/3035] vs 11.6% [847/7277], P = 1.5E−14), KEAP1 mutations (8.9% [271/3035] vs 5.3% [388/7277], P = 8.5E−10), and APOBEC mutational signature (6.0% [182/3035] vs 3.9% [286/7277], P = 1.7E−04) were significantly higher in the NSCLC-BM cohort when compared with the pNSCLC cohort (Table 2). This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.